Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zenas BioPharma (NASDAQ: ZBIO) has granted an inducement stock option to a new employee on June 16, 2025. The grant includes options to purchase 112,000 shares of common stock at an exercise price of $9.97 per share, matching the company's closing stock price on the grant date. The stock option has a ten-year term and follows a four-year vesting schedule, with 25% vesting after one year of employment and the remaining shares vesting in 36 equal monthly installments. This grant was approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and is subject to the employee's continued service with the company.

WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 112,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

The Inducement Grant has a ten-year term and an exercise price per share of $9.97, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with Zenas through the applicable vesting dates. The Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement.

About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com

FAQ

What is the exercise price of ZBIO's inducement stock option grant?

The exercise price of the inducement stock option grant is $9.97 per share, equal to Zenas BioPharma's closing stock price on June 16, 2025.

How many shares were included in ZBIO's inducement grant?

The inducement grant includes options to purchase 112,000 shares of Zenas BioPharma's common stock.

What is the vesting schedule for ZBIO's inducement stock option?

The stock option vests over 4 years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments.

How long is the term of ZBIO's inducement stock option grant?

The inducement stock option grant has a ten-year term.